TABLE 4

Association of LARG SNPs with diabetes-related phenotypes

GenotypeLARG-SNP6
LARG-SNP11
LARG-SNP12LARG-SNP15
LARG-SNP18
AA (n = 148)AG (n = 137)GG (n = 37)PAA (n = 165)AG (n = 133)GG (n = 24)PCC (n = 253)TT + CT (n = 69)PAA (n = 126)AG (n = 144)GG (n = 52)PTyr/Tyr (n = 100)Tyr/Cys (n = 171)Cys/Cys (n = 51)P
Male/females (n)89/5984/5318/190.37100/6582/519/150.08144/10943/260.4279/4778/6631/210.3663/3797/7429/220.57
Percent body fat32 ± 132 ± 133 ± 10.8532 ± 132 ± 133 ± 20.5732 ± 132 ± 10.4632 ± 132 ± 132 ± 10.3832 ± 132 ± 133 ± 10.49
2-h plasma glucose (mg/dl)121 ± 3126 ± 3131 ± 50.19121 ± 2126 ± 2138 ± 60.07125 ± 2124 ± 40.98120 ± 3128 ± 3127 ± 40.15128 ± 3124 ± 2120 ± 50.22
(log)2-h plasma insulin2.2 ± 0.12.2 ± 0.12.2 ± 0.10.602.1 ± 0.12.2 ± 0.12.3 ± 0.10.162.2 ± 0.12.2 ± 0.10.432.2 ± 0.12.2 ± 0.12.2 ± 0.10.432.2 ± 0.12.2 ± 0.12.1 ± 0.10.40
(log)glucose disposal for low-dose insulin clamp (mg · kg EMBS−1 · min−1)0.41 ± 0.010.39 ± 0.010.38 ± 0.020.220.41 ± 0.010.40 ± 0.010.36 ± 0.020.070.40 ± 0.010.39 ± 0.010.420.41 ± 0.010.39 ± 0.010.38 ± 0.010.080.37 ± 0.010.41 ± 0.010.43 ± 0.020.0001
Glucose disposal for high-dose insulin clamp (mg · kg EMBS−1 · min−1)9.1 ± 0.28.7 ± 0.28.0 ± 0.30.039.0 ± 0.28.7 ± 0.27.6 ± 0.40.028.8 ± 0.18.5 ± 0.30.169.2 ± 0.28.6 ± 0.28.3 ± 0.30.0088.3 ± 0.28.8 ± 0.29.5 ± 0.30.004
  • Data are means ± SE. P values were calculated after adjusting for age, sex, nuclear family membership for the variable percent body fat and for age, sex, percent body fat, and nuclear family membership for the variables 2-h plasma glucose (2 h after ingestion of 75 g glucose for oral glucose tolerance test), 2-h plasma insulin, and log10 glucose disposal for the physiologic and maximally stimulating insulin clamps. Due to the low frequency of the rare alleles for LARG-SNP12 variants, for statistical analysis, the homozygotes for each rare allele were combined with the heterozygotes; therefore, only a dominant effect on risk has been tested for the rare allele. EMBS, estimated metabolic body size.